"BRILACIDIN" George Mason University: Brilacidin
Post# of 72447
(Total Views: 531)
Posted On: 09/15/2022 4:44:05 PM
"BRILACIDIN" George Mason University:
Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against
Acutely Infectious Viruses
Carol Anderson1
, Michael Barrera
1
, Niloufar Boghdeh1
, Kyle Weston2
, Jane Harness
2
, Aarthi Narayanan1
1 George Mason University;
2
Innovation Pharmaceuticals
DISCUSSION/CONCLUSION
"The observations that we continue to make in experiments involving brilacidin in the context of acutely infectious viruses support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound. Several lines of evidence suggest that brilacidin may affect virion integrity and hence impact viral entry, thus positioning it well as a broad-spectrum prophylactic countermeasure solution. The observations about anti-inflammatory activities (data not shown) indicate that intracellular events are also modulated by brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing both viral and inflammatory load. Brilacidin has undergone several clinical studies as treatment for bacterial infections. Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the form of a nasally-delivered countermeasure"
MHSRS2022+-+Brilacidin+poster+fv.pdf (squarespace.com)
https://static1.squarespace.com/static/571535...ter+fv.pdf
Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against
Acutely Infectious Viruses
Carol Anderson1
, Michael Barrera
1
, Niloufar Boghdeh1
, Kyle Weston2
, Jane Harness
2
, Aarthi Narayanan1
1 George Mason University;
2
Innovation Pharmaceuticals
DISCUSSION/CONCLUSION
"The observations that we continue to make in experiments involving brilacidin in the context of acutely infectious viruses support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound. Several lines of evidence suggest that brilacidin may affect virion integrity and hence impact viral entry, thus positioning it well as a broad-spectrum prophylactic countermeasure solution. The observations about anti-inflammatory activities (data not shown) indicate that intracellular events are also modulated by brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing both viral and inflammatory load. Brilacidin has undergone several clinical studies as treatment for bacterial infections. Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the form of a nasally-delivered countermeasure"
MHSRS2022+-+Brilacidin+poster+fv.pdf (squarespace.com)
https://static1.squarespace.com/static/571535...ter+fv.pdf
(3)
(0)